Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptibleEscherichia colibloodstream infection
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Clinical Microbiology and Antimicrobials"
DOI: 10.1186/s12941-020-00400-z
Abstract: Background Cefiderocol, ceftazidime-avibactam, ceftolozane-tazobactam, intravenous fosfomycin and plazomicin represent potential carbapenem sparing agents for extended-spectrum-beta-lactamase or AmpC beta-lactamase producing Escherichia coli infection. However, available data is limited in predicting the volume of carbapenem therapy which… read more here.
Keywords: 100 patient; carbapenem sparing; infection; patient days ... See more keywords